한글목차

휴미라 세계 시장 규모는 2024년에 104억 1,000만 달러, 2030년에는 198억 4,000만 달러에 달할 것으로 예측되며, 예측 기간 동안 CAGR 11.32%로 성장할 것으로 예측됩니다.

류마티스 관절염, 건선성 관절염, 크론병, 궤양성 대장염, 강직성 척추염 등 자가면역질환 및 만성 염증성 질환의 유병률 증가로 인해 이 시장은 꾸준히 성장하고 있습니다. 노인 인구의 증가와 조기 진단 및 치료에 대한 인식 개선으로 휴미라(아달리무맙)와 같은 생물학적 제제의 처방 빈도가 증가하고 있습니다. 휴미라는 염증을 억제하고 장기적인 질환 관리를 개선하는 효과가 입증되어 류마티스내과, 소화기내과, 피부과 등 다양한 전문과에서 선호하는 치료제로 사용되고 있습니다. 또한, 새로운 적응증과 병용요법을 모색하는 임상시험을 통해 그 사용 범위가 넓어지고 있습니다. 주요 특허가 만료되었음에도 불구하고, 이 브랜드는 강력한 시장 입지를 유지하고 있습니다. 이는 투여 방법의 혁신, 환자 지원 프로그램, 바이오시밀러 의약품의 경쟁에 따른 영향을 줄이기 위한 전략적 라이선싱 활동 등에 힘입은 바 있습니다.

시장 촉진요인

자가면역질환 및 만성 염증성 질환의 유병률 상승

주요 시장 과제

특허 만료와 독점권 상실

주요 시장 동향

리얼월드에비던스(RWE)에 대한 수요 증가

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 휴미라 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 제품별(브랜드, 바이오시밀러)
  • 용도별(류마티스 관절염(RA), 건선성 관절염(PsA), 크론병(CD), 궤양성 대장염(UC), 강직성 척추염, 기타)
  • 유통 채널별(병원 약국, 소매 약국, 온라인 약국)
  • 기업별(2024)
  • 지역별
• 시장 맵

제6장 북미의 휴미라 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 휴미라 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 휴미라 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 휴미라 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 휴미라 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병
• 제품 출시
• 최근 동향

제13장 혼란 : 분쟁, 팬데믹, 무역장벽

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체품의 위협

제15장 경쟁 구도

• Alvotech
• Amgen Inc.
• Boehringer Ingelheim Pharmaceuticals, Inc.
• CELLTRION INC.
• Coherus BioSciences, Inc.
• Fresenius Kabi AG
• FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
• Pfizer Inc.
• Samsung Bioepis Co., Ltd.
• Sandoz Inc.

제16장 전략적 제안

제17장 조사 회사 소개 및 면책사항

영문목차

The Global Humira Market was valued at USD 10.41 Billion in 2024 and is projected to reach USD 19.84 Billion by 2030, growing at a CAGR of 11.32% during the forecast period. The market is witnessing steady growth, fueled by the increasing prevalence of autoimmune and chronic inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis. With a growing elderly population and improved awareness around early diagnosis and treatment, biologic therapies like Humira (adalimumab) are being prescribed more frequently. Humira's proven effectiveness in reducing inflammation and improving long-term disease management has made it a preferred treatment across various specialties, including rheumatology, gastroenterology, and dermatology. Additionally, its usage is being extended through clinical trials exploring new indications and combination therapies. Despite the expiration of key patents, the brand continues to maintain a strong market presence, aided by innovations in delivery methods, patient assistance programs, and strategic licensing efforts that help mitigate the impact of biosimilar competition.

Key Market Drivers

Rising Prevalence of Autoimmune and Chronic Inflammatory Diseases

The increasing incidence of autoimmune and chronic inflammatory disorders is a primary factor driving the Global Humira Market. According to the World Health Organization, approximately 18 million people were living with rheumatoid arthritis in 2019, with a 14.1% increase in global age-standardized prevalence since 1990. In the United States alone, psoriasis affects about 3% of the adult population, totaling over 7.5 million individuals.

This expanding patient base fuels the demand for biologic treatments like Humira, especially as healthcare providers are beginning therapy earlier in the disease course to prevent long-term complications. Greater public awareness and advocacy have also contributed to earlier diagnosis and intervention, making advanced immunotherapies more integral to treatment strategies. Humira's long-standing clinical use across multiple therapeutic areas has established it as a trusted option among physicians, reinforcing its continued adoption.

Key Market Challenges

Patent Expirations and Loss of Exclusivity

One of the most significant challenges facing the Global Humira Market is the expiration of its key patents and the resulting loss of market exclusivity. AbbVie's Humira enjoyed a dominant position due to robust patent protection, but the introduction of biosimilar adalimumab products has begun to erode its market share. These biosimilars offer similar efficacy at lower prices, prompting healthcare systems-particularly in cost-sensitive regions-to encourage their use as a cost-saving measure.

As biosimilar availability expands, insurers and pharmacy benefit managers are prioritizing them over the originator drug, increasing pressure on prescribers to switch treatments. This competitive shift is changing pricing dynamics and weakening Humira's revenue potential in markets where cost containment and accessibility are key concerns.

Key Market Trends

Rising Demand for Real-World Evidence (RWE)

A growing focus on Real-World Evidence (RWE) is shaping the Global Humira Market, as stakeholders seek comprehensive data on how treatments perform outside controlled clinical trials. With the rise of biosimilars and competitive pricing, regulators, payers, and clinicians are relying more on RWE to evaluate long-term outcomes, adherence rates, patient satisfaction, and comparative effectiveness across various populations.

RWE provides valuable insights into how therapies function in real-world settings, especially for patients with multiple conditions or inconsistent treatment patterns. These insights are crucial for making informed decisions about therapy options, reimbursement policies, and value-based care initiatives, particularly as the market adapts to increasing biosimilar usage.

Key Market Players

• Alvotech
• Amgen Inc.
• Boehringer Ingelheim Pharmaceuticals, Inc.
• CELLTRION INC.
• Coherus BioSciences, Inc.
• Fresenius Kabi AG
• FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
• Pfizer Inc.
• Samsung Bioepis Co., Ltd.
• Sandoz Inc.

Report Scope:

In this report, the Global Humira Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Humira Market, By Product:

• Branded
• Biosimilar

Humira Market, By Application:

• Rheumatoid Arthritis (RA)
• Psoriatic Arthritis (PsA)
• Crohn's Disease (CD)
• Ulcerative Colitis (UC)
• Ankylosing Spondylitis
• Others

Humira Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Humira Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Humira Market.

Available Customizations:

Global Humira Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Humira Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Branded, Biosimilar)
  • 5.2.2. By Application (Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Crohn's Disease (CD), Ulcerative Colitis (UC), Ankylosing Spondylitis, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Humira Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Humira Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Mexico Humira Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Canada Humira Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Distribution Channel

7. Europe Humira Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Humira Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Humira Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Humira Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Humira Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Humira Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Humira Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Humira Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Humira Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. South Korea Humira Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Japan Humira Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Humira Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Distribution Channel

9. South America Humira Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Humira Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Humira Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Humira Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Humira Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Humira Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Humira Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Humira Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Alvotech
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Amgen Inc.
• 15.3. Boehringer Ingelheim Pharmaceuticals, Inc.
• 15.4. CELLTRION INC.
• 15.5. Coherus BioSciences, Inc.
• 15.6. Fresenius Kabi AG
• 15.7. FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
• 15.8. Pfizer Inc.
• 15.9. Samsung Bioepis Co., Ltd.
• 15.10. Sandoz Inc.

16. Strategic Recommendations

17. About Us & Disclaimer